Results 51 to 60 of about 7,552 (172)

Drug induced liver injury: accuracy of diagnosis in published reports

Annals of Hepatology, 2014
The diagnosis of drug induced liver injury (DILI) is based primarily on the exclusion of alternative causes. To assess the frequency of alternative causes in initially suspected DILI cases, we searched the Medline database with the following terms: drug ...
Rolf Teschke, Christian Frenzel, Albrecht Wolff, Axel Eickhoff, Johannes Schulze   +4 more
doaj   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

British Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem, Mohannad N. AbuHaweeleh, Humam Emad Rajha, Mhd Osama Rahhal, Ahmad Hamdan, Lina Naseralallah   +5 more
wiley   +1 more source

The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury [PDF]

Expert Review of Gastroenterology & Hepatology, 2017
Drug-induced liver injury (DILI) is challenging for drug development, clinical practice and regulation. The Liver Toxicity Knowledge Base (LTKB) provides essential data for DILI study. Areas covered: The LTKB provided various types of data that can be used to assess and predict DILI.
Shraddha, Thakkar, Minjun, Chen, Hong, Fang, Zhichao, Liu, Ruth, Roberts, Weida, Tong   +5 more
openaire   +2 more sources

The Diagnosis and Manifestations of Liver Injury Secondary to Off-Label Androgenic Anabolic Steroid Use

Case Reports in Gastroenterology, 2016
Drug-induced liver injury (DILI) presents as a broad spectrum of adverse drug reactions which can range from a mild elevation in liver enzymes to fulminant liver failure.
Elena Cabb, Shanna Baltar, David Wes Powers, Karthik Mohan, Antonio Martinez, Eric Pitts   +5 more
doaj   +1 more source

Epigallocatechin-3-gallate Mo nanoparticles (EGM NPs) efficiently treat liver injury by strongly reducing oxidative stress, inflammation and endoplasmic reticulum stress

Frontiers in Pharmacology, 2022
Drug-induced liver injury (DILI) is a serious clinical disease associated with reactive oxygen species (ROS) burst and subsequent inflammatory responses.
Yunrong Yang, Yunrong Yang, Min Liu, Min Liu, Tianjiao Zhao, Tianjiao Zhao, Qiaohui Chen, Qiaohui Chen, Yuqi Yang, Yuqi Yang, Shuya Wang, Shuya Wang, Jinping Zhang, Jinping Zhang, Guiming Deng, Kewei Sun, Yayun Nan, Ke Cao, Kelong Ai, Kelong Ai, Qiong Huang, Qiong Huang   +21 more
doaj   +1 more source

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

British Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich   +12 more
wiley   +1 more source

Functional foods and bioactive compounds: a comprehensive review on their role in mitigating drug-induced liver injury

Frontiers in Nutrition
Drug-induced liver injury (DILI) has become a serious public health issue worldwide. Many drugs (chemotherapy drugs, fever-reducing medications, nonsteroidal anti-inflammatory drugs, immunosuppressants, antibiotics, antivirals, and antineoplastic drugs ...
Jin-Wei Zhao, Wei-Yi Zhao, Meng Zhao, Lu Yu   +3 more
doaj   +1 more source

Prediction of Acute Liver Injury Trajectory in Patients Following Acetaminophen Overdose: A Multibiomarker Machine Learning Proof‐of‐Concept Study

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical translation of novel therapies can be hindered by heterogeneity‐driven sample size inflation in late‐stage trials. In acetaminophen‐induced liver injury (APAP DILI), many patients recover spontaneously, diluting investigational drug efficacy signals.
Chris Humphries, Alastair M. Kilpatrick, Kathleen M. Scullion, Rhona Aird, Lorraine Bruce, Maria Elena Candela, Tak Yung Man, Stuart J. Forbes, James W. Dear   +8 more
wiley   +1 more source

Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug‐induced idiosyncratic liver injury (DILI) [PDF]

British Journal of Pharmacology, 2007
Background and purpose:The general view on the pathogenesis of drug‐induced idiosyncratic liver injury (DILI) is that parent compounds are rendered hepatotoxic by metabolism, mainly by cytochrome (CYP) 450, although other metabolic pathways can contribute. Anecdotal reports suggest a role of CYP 450 polymorphisms in DILI. We aimed to assess in a series
Pachkoria, K., Lucena-González, María Isabel, Ruiz-Cabello, Francisco, Crespo, Esperanza, Cabello-Porras, María Rosario, Andrade-Bellido, Raúl Jesús   +5 more
openaire   +4 more sources

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer   +4 more
wiley   +1 more source